Genetic polymorphisms of human β-defensins in patients with multiple sclerosis

Research output: Contribution to journalArticle

1 Citation (Scopus)


Aims: Recent studies have started to elucidate the contribution of microbiome to the pathogenesis of multiple sclerosis (MS). It is alsó supposed, that neuropathological alterations might be associated with abnormal expression and regulatory function of antimicrobial peptides (AMPs), including defensins. It is in our interest to investigate the relevance of the single nucleotide polymorphisms (SNPs) of the DEFB1 gene and the copy number polymorphism of the DEFB4 genes in MS. Methods: DEFB1 polymorphisms: C.-20G >A (rsl 1362), DEFB1 C.-44C > G (rsl 800972), DEFB1 c.-52G>A (rsl 799946), and the DEFB4 gene copy number were investigated in 250 MS patients The control patients comprised 232 age- and gender-matched healthy blood donors. The occurrence of the human β-defensin 2 peptide (hBD2) in the plasma of controis and patients was determined by ELISA. Results: The DEFB1 c.-44C>G polymorphism the GG protective genotype was much less frequent among patients than among the controis. A higher frequency of a lower (<4) copy number of the DEFB4 gene was observed in the patients with MS as compared with the controis (43% vs. 28%, respectively). The median levels of the circulating hBD2 in the patients were 150.6± 12.71 pg/ml vs. 262.1 ±23.82 pg/ml in the control group (p>0.0001). Our results suggest that β-defensins play role in the development of MS.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalIdeggyogyaszati szemle
Issue number3-4
Publication statusPublished - Mar 30 2015


  • Copy number
  • Human β-defensin
  • Multiple sclerosis
  • Polymorphism

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Genetic polymorphisms of human β-defensins in patients with multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this